Johanna Olweus
Overview
Explore the profile of Johanna Olweus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
904
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Champagne J, Nielsen M, Feng X, Montenegro Navarro J, Pataskar A, Voogd R, et al.
Immunity
. 2025 Jan;
58(1):247-262.e9.
PMID: 39755122
Prolonged exposure to interferon-gamma (IFNγ) and the associated increased expression of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) create an intracellular shortage of tryptophan in the cancer cells, which stimulates ribosomal...
2.
Giannakopoulou E, Lehander M, Virding Culleton S, Yang W, Li Y, Karpanen T, et al.
Nat Cancer
. 2023 Oct;
4(10):1474-1490.
PMID: 37783807
Acute myeloid leukemia (AML), the most frequent leukemia in adults, is driven by recurrent somatically acquired genetic lesions in a restricted number of genes. Treatment with tyrosine kinase inhibitors has...
3.
Spasevska I, Sharma A, Steen C, Josefsson S, Blaker Y, Kolstad A, et al.
Blood Adv
. 2023 Sep;
7(23):7216-7230.
PMID: 37695745
Tumor-infiltrating regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. Despite extensive studies, the prognostic impact of tumor-infiltrating Tregs in B-cell non-Hodgkin lymphomas (B-NHLs) remains unclear. Emerging studies suggest...
4.
Foldvari Z, Knetter C, Yang W, Gjerdingen T, Bollineni R, Tran T, et al.
NPJ Vaccines
. 2023 Aug;
8(1):126.
PMID: 37607971
Cancer immunotherapy using T cell receptor-engineered T cells (TCR-Ts) represents a promising treatment option. However, technologies for pre-clinical safety assessment are incomplete or inaccessible to most laboratories. Here, TCR-T off-target...
5.
Meyer S, Blaas I, Bollineni R, Delic-Sarac M, Tran T, Knetter C, et al.
Cell Rep
. 2023 Jan;
42(1):111995.
PMID: 36656713
The emergence of SARS-CoV-2 variants of concern (VOC) is driven by mutations that mediate escape from neutralizing antibodies. There is also evidence that mutations can cause loss of T cell...
6.
Pataskar A, Champagne J, Nagel R, Kenski J, Laos M, Michaux J, et al.
Nature
. 2022 Jul;
608(7922):E20.
PMID: 35840685
No abstract available.
7.
Ask E, Tschan-Plessl A, Gjerdingen T, Saetersmoen M, Hoel H, Wiiger M, et al.
Med
. 2022 May;
2(2):180-195.e5.
PMID: 35590201
Background: Current prognostic variables can only partly explain the large outcome heterogeneity in diffuse large B cell lymphoma (DLBCL). We aimed to investigate the utility of systems-level protein and immune...
8.
Bollineni R, Tran T, Lund-Johansen F, Olweus J
Curr Opin Immunol
. 2022 Mar;
75:102172.
PMID: 35279483
Neoantigens are commonly defined as HLA-bound peptides that are altered as a consequence of DNA damage and recognized by T cells. Current efforts to target neoantigens in therapy rely on...
9.
Pataskar A, Champagne J, Nagel R, Kenski J, Laos M, Michaux J, et al.
Nature
. 2022 Mar;
603(7902):721-727.
PMID: 35264796
Activated T cells secrete interferon-γ, which triggers intracellular tryptophan shortage by upregulating the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. Here we show that despite tryptophan depletion, in-frame protein synthesis continues across...
10.
Riise J, Meyer S, Blaas I, Chopra A, Tran T, Delic-Sarac M, et al.
Br J Haematol
. 2022 Mar;
197(6):697-708.
PMID: 35254660
B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)...